TY - JOUR
T1 - Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study
AU - Song, Honglin
AU - Ramus, Susan J.
AU - Kjaer, Susanne Krüger
AU - DiCioccio, Richard A.
AU - Chenevix-Trench, Georgia
AU - Pearce, Celeste Leigh
AU - Hogdall, Estrid
AU - Whittemore, Alice S.
AU - McGuire, Valerie
AU - Hogdall, Claus
AU - Blaakaer, Jan
AU - Wu, Anna H.
AU - Van Den Berg, David J.
AU - Stram, Daniel O.
AU - Menon, Usha
AU - Gentry-Maharaj, Aleksandra
AU - Jacobs, Ian J.
AU - Webb, Penny M.
AU - Beesley, Jonathan
AU - Chen, Xiaoqing
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A.
AU - Chang-Claude, Jenny
AU - Wang-Gohrke, Shan
AU - Goodman, Marc T.
AU - Lurie, Galina
AU - Thompson, Pamela J.
AU - Carney, Michael E.
AU - Ness, Roberta B.
AU - Moysich, Kirsten
AU - Goode, Ellen L.
AU - Vierkant, Robert A.
AU - Cunningham, Julie M.
AU - Anderson, Stephanie
AU - Schildkraut, Joellen M.
AU - Berchuck, Andrew
AU - Iversen, Edwin S.
AU - Moorman, Patricia G.
AU - Garcia-Closas, Montserrat
AU - Chanock, Stephen
AU - Lissowska, Jolanta
AU - Brinton, Louise
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Brewster, Wendy R.
AU - Ponder, Bruce A.J.
AU - Easton, Douglas F.
AU - Gayther, Simon A.
AU - Pharoah, Paul D.P.
N1 - Funding Information:
We thank all the individuals who took part in this study. We thank: Hannah Munday, Barbara Perkins, Mitul Shah, Clare Jordan, Judy West, Anabel Simpson, Sue Irvine, Anne Stafford, the SEARCH team: the local general practices and nurses and the Eastern Cancer Registry for recruitment of the UK cases and the EPIC-Norfolk investigators for recruitment of the UK controls for SEA study; We thank all members of the research team, including research nurses, research scientists, data entry personnel and consultant gynae- cological oncologists for their help in establishing the UKOPS case–control collection, particularly we thank Eva Wozniak for the efforts in genotyping and Andy Ryan and Jeremy Ford for data and sample management for UKO study. We thank Ursula Eilber and Tanja Koehler for competent technical assistance for German Ovarian Cancer study. The AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see http://www.aocstudy.org/). The AOCS and ACS Management Group (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all of the project staff, collaborating institutions and study participants. We thank all the funding agencies and institutions for their support. D.F.E. is a Principal Research Fellow of Cancer Research UK, P.D.P.P. is CRUK Senior Clinical Research Fellow. S.J.R. is supported by the Mermaid/Eve Appeal, G.C.T. and P.W. are supported by the NHMRC.
Funding Information:
This work was supported by Cancer Research UK, The Roswell Park Alliance, The Danish Cancer Society and The National Cancer Institute (CA71766, CA16056, RO1 CA61107 and RO1 CA122443). We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of OCAC through their donations to the Ovarian Cancer Research Fund. US Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study), The National Health and Medical Research Council of Australia (199600) (ACS study). DOV study was supported by the US national Cancer Institute grants R01 CA87538 and R01 CA112523. The German Ovarian Cancer Study was supported by the German Federal Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research grant 01 GB 9401 and the genotyping in part by the state of Baden-Württemberg through Medical Faculty of the University of Ulm (P.685). HAW study was supported by US Public Health Service grant R01-CA-58598, and contracts N01-CN-55424 and N01-PC-35137 from the National Cancer Institute, NIH, Department of Health and Human Services. UCI study was supported by the National Institutes of Health, National Cancer Institute grants CA-58860, CA-92044 and the Lon V Smith Foundation grant LVS-39420. The UKOPS study is funded by the OAK Foundation. Some of this work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre funding scheme.
PY - 2009
Y1 - 2009
N2 - Because both ovarian and breast cancer are hormone-related and are known to have some predisposition genes in common, we evaluated 11 of the most significant hits (six with confirmed associations with breast cancer) from the breast cancer genome-wide association study for association with invasive ovarian cancer. Eleven SNPs were initially genotyped in 2927 invasive ovarian cancer cases and 4143 controls from six ovarian cancer case-control studies. Genotype frequencies in cases and controls were compared using a likelihood ratio test in a logistic regression model stratified by study. Initially, three SNPs (rs2107425 in MRPL23, rs7313833 in PTHLH, rs3803662 in TNRC9) were weakly associated with ovarian cancer risk and one SNP (rs4954956 in NXPH2) was associated with serous ovarian cancer in non-Hispanic white subjects (P-trend < 0.1). These four SNPs were then genotyped in an additional 4060 cases and 6308 controls from eight independent studies. Only rs4954956 was significantly associated with ovarian cancer risk both in the replication study and in combined analyses. This association was stronger for the serous histological subtype [per minor allele odds ratio (OR) 1.07 95% CI 1.01-1.13, P-trend = 0.02 for all types of ovarian cancer and OR 1.14 95% CI 1.07-1.22, P-trend = 0.00017 for serous ovarian cancer]. In conclusion, we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer. However, none of the six confirmed breast cancer susceptibility variants we tested was associated with ovarian cancer risk. Further work will be needed to identify the causal variant associated with rs4954956 or elucidate its function.
AB - Because both ovarian and breast cancer are hormone-related and are known to have some predisposition genes in common, we evaluated 11 of the most significant hits (six with confirmed associations with breast cancer) from the breast cancer genome-wide association study for association with invasive ovarian cancer. Eleven SNPs were initially genotyped in 2927 invasive ovarian cancer cases and 4143 controls from six ovarian cancer case-control studies. Genotype frequencies in cases and controls were compared using a likelihood ratio test in a logistic regression model stratified by study. Initially, three SNPs (rs2107425 in MRPL23, rs7313833 in PTHLH, rs3803662 in TNRC9) were weakly associated with ovarian cancer risk and one SNP (rs4954956 in NXPH2) was associated with serous ovarian cancer in non-Hispanic white subjects (P-trend < 0.1). These four SNPs were then genotyped in an additional 4060 cases and 6308 controls from eight independent studies. Only rs4954956 was significantly associated with ovarian cancer risk both in the replication study and in combined analyses. This association was stronger for the serous histological subtype [per minor allele odds ratio (OR) 1.07 95% CI 1.01-1.13, P-trend = 0.02 for all types of ovarian cancer and OR 1.14 95% CI 1.07-1.22, P-trend = 0.00017 for serous ovarian cancer]. In conclusion, we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer. However, none of the six confirmed breast cancer susceptibility variants we tested was associated with ovarian cancer risk. Further work will be needed to identify the causal variant associated with rs4954956 or elucidate its function.
UR - http://www.scopus.com/inward/record.url?scp=66149156222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66149156222&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddp138
DO - 10.1093/hmg/ddp138
M3 - Article
C2 - 19304784
AN - SCOPUS:66149156222
SN - 0964-6906
VL - 18
SP - 2297
EP - 2304
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 12
ER -